We are excited to announce that Polaris has signed an agreement to acquire a majority stake in Salfarm, a Danish Animal Pharma player, with the aim of establishing a leading player in the Nordic Animal Health market. Shortly after the transaction, Salfarm has, in collaboration with Polaris, acquired the Finnish veterinary pharma player, FaunaPharma, strengthening Salfarm’s presence in Finland.
Salfarm was founded in 1979 and has grown to become a leading Danish player within animal pharmaceuticals with a presence throughout the Nordics delivering a +10% annual growth rate over a ten-year period. Headquartered in Kolding, Denmark, Salfarm owns subsidiaries in Sweden, Norway, and as of recently Finland, following the acquisition of FaunaPharma.
“We are very impressed by the journey that Salfarm has undergone. Today, Salfarm is a leading Danish player within animal pharmaceuticals, recognized by both suppliers and customers as a key partner and market expert in the Nordic region. Building on the strong team at Salfarm and their deep competencies and relationships, the ambition is to strengthen and grow Salfarm’s position outside of Denmark and establish a leading player in the Nordic market. The acquisition of FaunaPharma has been a first step on this journey,” says Simon Damkjær Wille, Partner at Polaris.
Please see the following press release:
For further information, please contact:
Simon Damkjær Wille, Partner
Phone: +45 4220 9639
Mail: sw@polarisequity.dk
Camilla Ringsted, Associate Director
Phone: +45 2968 6909
Mail: cri@polarisequity.dk
